Developing a platform to create therapeutic exosomes for drug delivery
A Convergent Bioengineered Platform for Multifunctional Therapeutic Exosomes
['FUNDING_OTHER'] · UNIVERSITY OF NOTRE DAME · NIH-10910010
This study is exploring a new way to make tiny delivery vehicles called exosomes that can carry cancer-fighting drugs right to the areas that need them, which could help patients get better treatment with fewer side effects.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF NOTRE DAME (nih funded) |
| Locations | 1 site (NOTRE DAME, UNITED STATES) |
| Trial ID | NIH-10910010 on ClinicalTrials.gov |
What this research studies
This research focuses on creating a bioengineered platform that efficiently manufactures therapeutic exosomes, which are tiny vesicles that can carry drugs. The approach involves loading anticancer drugs and therapeutic nucleic acids into these exosomes, enhancing their ability to deliver treatment directly to targeted areas in the body. By utilizing exosomes, the research aims to improve drug delivery across the blood-brain barrier and enhance the effectiveness of cancer therapies. Patients may benefit from more effective treatments with fewer side effects compared to traditional drug delivery methods.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancer who may benefit from advanced drug delivery systems.
Not a fit: Patients with non-cancerous conditions or those not requiring drug delivery improvements may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted cancer treatments with reduced side effects.
How similar studies have performed: Other research has shown promising results using exosomes for drug delivery, indicating potential success for this approach.
Where this research is happening
NOTRE DAME, UNITED STATES
- UNIVERSITY OF NOTRE DAME — NOTRE DAME, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WANG, YICHUN — UNIVERSITY OF NOTRE DAME
- Study coordinator: WANG, YICHUN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, Cancer Drug, Cancer Treatment